This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mostaza, J. M. Articles by Martín-Jadraque, L. Search for Related Content PubMed PubMed Citation Articles by Mostaza, J. M. Articles by Martín-Jadraque, L.

Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels

Jose M. Mostaza, MD, PhD^a, María V. Gomez, MD, PhD^a, Felix Gallardo, MD^a, María L. Salazar, MD, PhD^b, Raquel Martín-Jadraque, MD, PhD^a, Leandro Plaza-Celemín, MD^b, Isidoro Gonzalez-Maqueda, MD, PhD and Luís Martín-Jadraque, MD, PhD

^a Atherosclerosis Unit, Nuclear Medicine Service of the Centro de Investigaciones Clínicas del Instituto de Salud Carlos III, Madrid, Spain
^b the Atherosclerosis Unit, Cardiology Service of the Centro de Investigaciones Clínicas del Instituto de Salud Carlos III, Madrid, Spain
Coronary Unit of Hospital "La Paz," Madrid, Spain

View larger version (23K): [in a new window]   Figure 1 Visual scoring of SPECT images: summed stress score and summed rest score for each of the 18 patients in the study during placebo and pravastatin treatment.

View larger version (145K): [in a new window]   Figure 2 Short-axis slices from one representative patient during dipyridamole stress testing. There is a severe defect in the anterior and septal segments with placebo (arrows, upper panels) that partially reverses with pravastatin treatment (arrows, lower panels).

View larger version (100K): [in a new window]   Figure 3 Polar map display and quantitative analysis of the SPECT study obtained in the same patient represented in Figure 2. The images were obtained during dipyridamole stress and at rest, after placebo (upper panel) and pravastatin treatment (lower panel). The percentage of perfusion defect is represented for each of three vascular territories (LAD = left anterior descending; RCA = right coronary artery; LCX = left circumflex) and for the total left ventricle.